GLIS重排是甲状腺透明梁状肿瘤的基因组标志
本研究通过全外显子、RNA测序和靶向测序分析透明梁状肿瘤(HTT)的驱动突变,发现PAX8-GLIS3融合在盲法病理复核确认的HTT中占93%(13/14),PAX8-GLIS1占7%(1/14),而220例甲状腺乳头状癌(PTC)中无PAX8-GLIS3、仅1例PAX8-GLIS1。融合导致GLIS3/GLIS1的3'端mRNA过表达及细胞外基质基因上调,免疫组化证实胶原IV沉积。在10,165例细针穿刺样本中前瞻性检出8例PAX8-GLIS3(0.1%),其中5例手术病理均为HTT。作者建议将HTT更名为「GLIS重排透明梁状腺瘤」。
要点
- PAX8-GLIS3是HTT的高频驱动融合,在确认的HTT中占93%。
- PTC中未见PAX8-GLIS3,有助于鉴别HTT与PTC。
- 细针穿刺检出PAX8-GLIS3提示HTT,可辅助细胞学诊断。
核心结论
- GLIS重排(尤其PAX8-GLIS3)在HTT中高度流行,而在PTC中未检出PAX8-GLIS3。
- 融合导致GLIS过表达、细胞外基质基因上调及胶原沉积,解释HTT的组织学特征。
- 鉴于独特遗传机制和惰性行为,建议将HTT更名为「GLIS重排透明梁状腺瘤」。
研究设计与样本
- 研究对HTT进行全外显子、RNA-Seq和靶向下一代测序分析。
- 在17例初诊HTT、220例PTC和10,165例甲状腺细针穿刺样本中研究GLIS融合的患病率。
- 采用Sanger测序和FISH验证融合,免疫组化检测GLIS3和胶原表达。
主要发现
- 初诊3例HTT中未发现已知甲状腺肿瘤突变,但均检出PAX8外显子2与GLIS3外显子3的框内融合。
- 盲法病理复核确认的14例HTT中,13例(93%)检出PAX8-GLIS3,1例(7%)检出PAX8-GLIS1。
- 220例PTC中无PAX8-GLIS3融合,仅1例检出PAX8-GLIS1。
- 10,165例细针穿刺样本中前瞻性检出8例(0.1%)PAX8-GLIS3,其中5例手术病理均为HTT。
- 融合导致含完整DNA结合域的GLIS3和GLIS1 mRNA 3'端过表达,并上调胶原IV等细胞外基质基因。
临床怎么用
- 对细胞学不确定的甲状腺结节,检测PAX8-GLIS3融合有助于提示HTT。
- HTT与PTC的遗传机制不同,GLIS重排可作为鉴别诊断标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyalinizing trabecular tumor (HTT) is a rare thyroid neoplasm with a characteristic trabecular growth pattern and hyalinization. This lesion has been the subject of long-term controversy surrounding its genetic mechanisms, relationship to papillary thyroid carcinoma (PTC), and malignant potential. Due to the presence of nuclear features shared with PTC, HTT frequently contributes to a false-positive cytology, which hampers patient management. The goal of this study was to apply genome-wide sequencing analyses to elucidate the genetic mechanisms of HTT and its relationship to PTC. METHODS: Whole-exome, RNA-Seq, and targeted next-generation sequencing analyses were performed to discover and characterize driver mutations in HTT. RNA-Seq results were used for pathway analysis. Tissue expression of GLIS3 and other proteins was detected by immunohistochemistry. The prevalence of GLIS fusions was studied in 17 tumors initially diagnosed as HTT, 220 PTC, and 10,165 thyroid fine-needle aspiration samples. RESULTS: Using whole-exome and RNA-Seq analyses of the initial three HTT, no known thyroid tumor mutations were identified, while in-frame gene fusion between PAX8 exon 2 and GLIS3 exon 3 was detected in all tumors. Further analysis identified PAX8-GLIS3 in 13/14 (93%) and PAX8-GLIS1 in 1/14 (7%) of HTT confirmed after blind pathology review. The fusions were validated by Sanger sequencing and FISH. The fusions resulted in overexpression of the 3'-portion of GLIS3 and GLIS1 mRNA containing intact DNA-binding domains of these transcription factors and upregulation of extracellular matrix genes including collagen IV. Immunohistochemistry confirmed upregulation and deposition of collagen IV and pan-collagen in HTT. The analysis of 220 PTC revealed no PAX8-GLIS3 and one PAX8-GLIS1 fusion. PAX8-GLIS3 was prospectively identified in 8/10,165 (0.1%) indeterminate cytology fine-needle aspiration samples; 5/5 resected fusion-positive nodules were HTT on surgical pathology. CONCLUSIONS: This study demonstrates that GLIS rearrangements, particularly PAX8-GLIS3, are highly prevalent in HTT but not in PTC. The fusions lead to overexpression of GLIS, upregulation of extracellular matrix genes, and deposition of collagens, which is a characteristic histopathologic feature of HTT. Due to unique genetic mechanisms and an indolent behavior, it is proposed to rename this tumor as "GLIS-rearranged hyalinizing trabecular adenoma."
引用
- Nikiforova MN, Nikitski AV, Panebianco F, et al. GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. Thyroid. 2019. PMID: 30648929. doi:10.1089/thy.2018.0791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。